SUPN
Supernus Pharmaceuticals, Inc. (SUPN) ESG Analysis Analysis (2026)
Environmental
SUPN’s R&D intensity is elevated versus many specialty pharma peers, supporting lower-waste innovation but also implying a research-heavy operating footprint.
The company’s capital-light balance sheet reduces financing-related environmental exposure relative to more levered peers, limiting indirect resource intensity.
No disclosed emissions, energy, or water metrics were provided, so environmental positioning cannot be credited above peers with stronger disclosure and verified targets.
Overall environmental performance appears middling because innovation intensity is favorable, yet the absence of measurable climate and resource disclosures weakens peer-relative confidence.
Social
High gross margin and sustained R&D spending can support patient access and product quality, but these indicators do not by themselves establish superior social performance versus peers.
Stock-based compensation at roughly 7.0% of revenue suggests moderate employee alignment, though it is not clearly better than peer norms in specialty pharma.
No workforce safety, turnover, diversity, or product-access disclosures were provided, limiting evidence of stronger labor or patient outcomes relative to peers.
Social positioning is therefore moderate because the available data show some stakeholder alignment, but not enough disclosed evidence to outperform peers convincingly.
Governance
Debt-to-equity is very low, which reduces creditor pressure and supports governance flexibility relative to more highly levered peers.
Net debt to EBITDA is elevated, but the small absolute debt load suggests the ratio is less structurally concerning than it would be for capital-intensive peers.
Stock-based compensation remains meaningful, yet it is not excessive enough from the provided data to indicate materially weaker capital discipline than peers.
Governance looks stronger than average because conservative leverage and moderate compensation intensity reduce agency and balance-sheet risk versus many biotech and pharma peers.
Overall Score
SUPN’s ESG profile is moderate overall because governance is relatively stronger, while environmental and social positioning remain constrained by limited disclosed metrics versus peers.
Score Driver: Conservative Leverage And Moderate Compensation Discipline Are The Clearest Peer-Relative Strengths.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Supernus Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

